Trial Information

Phase 2, MultiCenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the treatment of Low Risk, Localized (T1c) Prostate Cancer

The purpose of the study is to determine the safety and efficacy of the investigational drug NX-1207 for the adjunctive treatment of T1c low -risk localized prostate cancer.
The study will evaluate 2 dosage levels as an adjunct to active surveillance versus active surveillance alone with no active treatment.

Patient Inclusion Criteria:
To be eligible for this study, subjects must:

Be Male aged 45-85
Have T1c carcinoma of the prostate with only one positive biopsy core
Have serum PSA < 10 ng/mL

Patient Exclusion Criteria:

Previous active treatment (such as surgery, brachytherapy, radiotherapy) for prostate cancer
Evidence of metastatic disease or previous positive bone scan
Previous hormonal therapy for prostate cancer

Eligible participants will receive study-related medical exams, lab tests, and study medication at no cost.

Donna Ammirati, Research Coordinator
Advanced Urology Centers of New York, Garden City Central Research Department
601 Franklin Avenue
Suite 300
Garden City, NY 11530
Phone: 516-742-3200 extension 302
Fax: 516-742-3260
Email: dammirati@imppllc.com

View Map

Research Center Information: Advanced Urology Centers of New York, Garden City Central Research Department

If you would like to learn more about participating in this study, please send an email message using the form below.

Name:
Address:
City:
State:
Country:
Phone:
Email:
Message:

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.